Traditional pharmaceutical R&D follows sequential, siloed pipelines where a single compound progresses through 10-15 years of development. Hypothesis: Networks of specialized BioDAOs (e.g., VitaDAO for longevity, CryoDAO for cryopreservation, CerebrumDAO for neurodegeneration) that share research data openly and test hypotheses in parallel across distributed labs can compress the average time-to-clinical-candidate from 5-7 years to under 18 months for small molecule and biologic therapeutics. This acceleration emerges from three mechanisms: (1) elimination of redundant negative results through shared failure databases, (2) cross-pollination of methodologies between disease domains (e.g., longevity insights applied to neurodegeneration), and (3) community-driven prioritization that selects for patient-relevant targets rather than commercially-driven ones. Testable prediction: BioDAOs sharing data through open IP-NFT registries will produce 10x more novel therapeutic candidates per dollar invested compared to traditional pharma R&D pipelines over a 5-year period.